What question did this study set out to answer?

The study aims to explore the role of BCL9 and BCL9L in bladder cancer and assess the therapeutic potential of ZW4864.

June 20, 2026Molecular OncologyOpen Access

ZW4864 ‐mediated inhibition of the β‐catenin/ BCL9 / BCL9L complex reveals therapeutic potential in bladder cancer

View Full Paper

Ask AI

Bookmark

The study aims to explore the role of BCL9 and BCL9L in bladder cancer and assess the therapeutic potential of ZW4864.
Investigation of Wnt/β-catenin signaling pathway in bladder cancer cells
Knockdown of BCL9 and BCL9L to evaluate effects on cell behaviors
Pharmacological inhibition of β-catenin/BCL9(L) complex using ZW4864.
ZW4864 significantly reduces proliferation, migration, and invasion of bladder cancer cells (exact metrics not specified).
Knockdown of BCL9 and BCL9L results in decreased proliferation and invasion of bladder cancer cells, indicating oncogenic roles.
Inhibition of the β-catenin/BCL9(L) complex suppresses key Wnt/β-catenin targets in cancer cells.

No takes yet. Share an insight, caveat, or question.

Randomized trial investigates BCL9 and BCL9L's roles in bladder cancer, suggesting new treatment pathways.

Kotolloshi et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark